

Real Problems. Real Solutions.

Runaway specialty drug costs and late-stage diagnoses are primary drivers of plan instability. We are here to help.

MapperHealth and Mayo Clinic, have developed a suite of genomic health solutions that replace clinical guesswork with DNA-guided precision. By combining disease risk insights with personalized medication guidance, MapperHealth moves your plan from reactive crisis management to proactive, data-driven interventions.



Genomic Health Program

The **Mayo Clinic Genomic Health Program** (powered by MapperHealth) provides proactive insights into **12 life-threatening conditions**, including **six of the seven leading causes of death in the United States**. Up to **85%** of life-threatening conditions, like breast cancer, are **not** explained by family history. The Genomic Health Program identifies high-risk disease an average of **8.9–10.8 years earlier** than standard screening, allowing patients and their doctors to manage potential health risks proactively, with lower-cost interventions. These early interventions **reduce premature death in 23.3% of high-risk patients** and provide insights for anyone looking to optimize their health.

MAYO CLINIC

Patient Name: (REDACTED)
Sample ID: (REDACTED)
Collection Location: SC

Date of Birth: (REDACTED)
Ordering Provider: Dr. Victor Griggs
Date Collected: 2025-09-30

MNM: (REDACTED)
Account Info: Mayo Clinic Labs
Report Date: 05/12/2026

Genomic Health Report

ASSESSED CONDITION	POLYGENIC RISK (PRS)	ODDS RATIO	PERCENTILE	DETAILS
Alzheimer's Disease	Average	0.6x	4th	Pg. 2
Atrial Fibrillation	Average	0.8x	30th	Pg. 3
Breast Cancer	Average	1.0x	58th	Pg. 4
Colorectal Cancer	Increased	2.0x	95th	Pg. 5
Coronary Artery Disease	Average	1.5x	87th	Pg. 6
Heart Failure	Average	1.2x	74th	Pg. 7
Hypertension	Average	1.0x	54th	Pg. 8
Type 2 Diabetes	Average	1.7x	72nd	Pg. 9
Venous Thromboembolism	Increased	0.6x	18th	Pg. 10
Venous Thromboembolism	Increased	4.3x	99th	Pg. 11
Appendix	Additional information about this test.			Pg. 12

Increased Polygenic Risk Score Identified

This patient's results show an increased polygenic risk score for 2 of the 10 conditions tested: Colorectal Cancer, Venous Thromboembolism

How to Use This Report

This report is designed to help you and your healthcare team create a personalized plan for screening and prevention. It is important to remember that these results are **not a diagnosis**, nor guarantee you will develop a specific condition. The "Odds Ratio" score (e.g., 2.0x) compares the patient's genetics to people who have already been diagnosed with a condition. Values above 1.0x indicate a higher polygenic risk score (2.0x threshold for "increased"), while values below 1.0x indicate reduced chance of disease. All findings should be considered with other factors (lifestyle, medication, clinical tests). In some cases, your provider may even recommend screening earlier or more often than standard guidelines suggest to stay proactive. Detailed results for each condition can be found on the pages listed in the summary table.



Personalized Medication Program

The **Mayo Clinic Personalized Medication Program** (powered by MapperHealth) identifies medications likely to be safe and effective while flagging those that are ineffective or potentially dangerous. This comprehensive solution covers **328 conditions** and over **6,500 medications**, with **91.6% of patients** receiving DNA-guided recommendations. This drives superior health outcomes and **\$20,687** average annual savings per patient sequenced, and an average **8.5x to 13x ROI** for the plan. MapperHealth **guarantees** that the employer's medical and pharmacy spend savings will exceed the total cost of sequencing, or we refund the difference.

MAYO CLINIC



Patient: Mario Gomez | DOB: 12/05/1976 | MNM: 14770801

Interpreting Pharmacist: Adam Sill, PharmD, BCACP | Report Date: May 4, 2024

Page 1 of 3

Personalized Medication Program

Date of Birth: 12/05/1976 - MNM: 14770801

Interpreting Pharmacist: Adam Sill, PharmD, BCACP - Mayo Genomic Health Lab

SAFETY OVERVIEW

Pharmacogenomic Safety Assessment

✓ No pharmacogenomic safety concerns were identified for your current medications.

REPORT NAVIGATION

Report Contents

High Cholesterol — Overview & Current Therapy

Page 2

High Cholesterol — Medication Details

Page 3

How to Use This Report

This report is designed to help you and your healthcare team select the most effective medications at the safest doses for your current health needs. Your results provide a detailed look at how your genetic profile affects the way your body processes specific drugs.

This assessment prioritizes the medications and health conditions you identified as most important today. While your genetics remain the same, your medication needs can change over time, meaning a follow-up review may be needed in the future. It is important to remember that genetics are only one piece of the puzzle. Lifestyle, age, and other medications also play a role in your health. Always consult your pharmacist or physician before making changes to your regimen.

For additional details, contact MapperHealth



sales@mapperhealth.com



1-800-950-3230



www.mapperhealth.com



Rheumatoid Arthritis

Intervention: Personalized Medication Report identified safe, effective generic tablet

Outcome: Switched to \$22/mo generic tablet: safe, effective and easy to take.

Saving: \$75,300 annually

Colorectal Cancer

Intervention: Genomic Health Report found HIGH polygenic risk; Recommended age 40 screening.

Outcome: Precancerous polyp removed; patient remains cancer-free.

Savings: \$97,000+

Breast Cancer

Intervention: Genomic Health Report found HIGH polygenic risk; immediate MRI.

Outcome: Stage 1 cancer discovered and treated early; cancer is in remission.

Savings: \$147,000+

Integrate through Benecon



Plan Integration

Summary Plan Descriptions (SPD) are incorporated by reference into your existing plan.



Member Eligibility Coordination

Member eligibility is provided by the group/consultant directly to HealthMapper.



Billing/Cost

\$2.75 PMPM (All-in access to both platforms).

\$250 Sequencing Fee (80% discount from the \$1,250 retail cost).

Money-Back Guarantee: MapperHealth guarantees that the employer's medical and pharmacy spend savings will exceed the total cost of sequencing, or we refund the difference.

The PMPM fee is converted to a PEPM fee and billed through Benecon. Neither the PEPM fee nor the sequencing fee is currently covered under stop loss. Benecon's billing is provided solely as a convenience.



Visit our website to learn more!



To elect MapperHealth, contact your consortium account manager. This option can be added during the renewal process or at any time throughout the year.

The Benecon Group, LLC, ConnectCare3, LLC, and the VERIS Benefits Consortium, LLC, provide vendor options as potential resources based on internal evaluations. These are not endorsements or guarantees of services or performance. No affiliation exists beyond these recommendations unless stated otherwise. Employer groups, their consultants, and legal counsel are responsible for verifying that any vendor or service does not violate existing contracts (including RX rebates) and for conducting independent due diligence. The above entities are not responsible for determining employer or participant eligibility for any vendor programs or services. All decisions to engage vendors are made solely at the employer group's discretion and risk. The above entities do not provide legal advice and disclaim liability for any outcomes from vendor use. Legal consultation is strongly advised before making plan changes.

For additional details, contact MapperHealth



sales@mapperhealth.com



1-800-950-3230



www.mapperhealth.com